On the fly News and insights, exclusive to thefly.com



$9.37 /

-3.47 (-27.02%)


Celyad sinks over 20% after 2M share offering prices at discount

Shares of Celyad are falling after the company announced the pricing of a global offering of 2M ordinary shares, comprised of 1,717,391 ordinary shares in the form of American Depositary Shares offered in the United States, Canada and certain countries outside of Europe at a price per of $10.00 per ADS. Shares of Celyad are down 21%, or $2.62, to $9.69 in morning trading. Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based product candidates. The company's lead clinical candidate, CYAD-01, is currently being evaluated in Phase 1 clinical trials for the treatment of hematological malignancies, such as acute myeloid leukemia, and solid cancers, such as metastatic colorectal cancer.

  • 12


CYAD Celyad
$9.37 /

-3.47 (-27.02%)

07/05/19 H.C. Wainwright
Celyad target lowered to $48 on new launch timeline at H.C. Wainwright
07/05/19 Piper Sandler
Celyad price target lowered to $25 from $41 at Piper Jaffray
06/17/19 Truist
Celyad selloff a buying opportunity, says SunTrust
06/17/19 Piper Sandler
Piper Jaffray reiterates Overweight on Celyad after EHA update

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.